entertainment -WSS

entertainment

author：focus 2025-10-04 03:59:27 - browse：8

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： FDA approves Moderna’s RSV vaccine, its second licensed product

Wikipedia

WSS

The Readout: Amylyx, Alumis, and Lundbeck drug updates

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Change Healthcare payments predicted restored March 15

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

First medicine developed to treat MASH expected to be approved soon

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

focus

entertainment

explore

The high cost of giving birth even with insurance

Just how do doctors, lawmakers, and the public define abortion?

Dobbs anniversary: the lost opportunity of abortion as health care

Amylyx ALS drug failure raises questions and concerns

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

RSV shot was 90% effective at preventing hospitalizations in kids

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare Advantage's lean provider networks lead CMS complaints

As demand for Covid shots wanes, Moderna seeks its next success

Sutter Health’s antitrust win overturned by appeals court

hotspot

STAT wants to know your pick for a great summer read or listen

Amylyx ALS drug fails large clinical trial

Sutter Health’s antitrust win overturned by appeals court

First medicine developed to treat MASH expected to be approved soon

Congress needs to close a vaccine

Structure Therapeutics oral GLP

focus

knowledge

Wikipedia

Wikipedia